Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783156 | 0.87 | CCR5 (0.49) | KEAP1NFE2L2PTGER1LRRK2ALDH1A1 | |
| SCHEMBL12121776 | 0.82 | PTGER1 (0.46) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL1990348 | 0.80 | PTGER1 (0.51) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL1990350 | 0.80 | PTGER1 (0.51) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL13957662 | 0.79 | MAPT (0.50) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL4000311 | 0.79 | PTGER1 (0.55) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL1989522 | 0.78 | PTGER1 (0.46) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL1989523 | 0.78 | PTGER1 (0.46) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL4832151 | 0.77 | GAA (0.48) | KEAP1NFE2L2PTGER1PTGER4PTGER3 | |
| SCHEMBL13257883 | 0.77 | KMT2A (0.47) | KEAP1NFE2L2PTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-7355077-B2 | Process for preparing tolterodine | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-08 | — | — | US | disclosed |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | ADRA2B, ADRB3, ADRB1 | KEAP1 1954/4885NFE2L2 3453/4885PTGER1 2052/4885 |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | ADRB3, UGT1A3, COMT | KEAP1 2168/4885NFE2L2 2786/4885PTGER1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.